The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 3, 2005, Pages 5-11

  Keck Jr , Paul E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LITHIUM; LITHIUM CARBONATE; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ABDOMINAL PAIN; AGITATION; AKATHISIA; ANOREXIA; ANXIETY; ASTHENIA; ATAXIA; BIPOLAR MANIA; COGNITIVE DEFECT; CONSTIPATION; DELIRIUM; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSPEPSIA; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; HYPERKINESIA; LETHARGY; LEUKOPENIA; MONOTHERAPY; MUSCLE HYPERTONIA; NAUSEA; NERVOUSNESS; NYSTAGMUS; OPHTHALMOPLEGIA; ORTHOSTATIC HYPOTENSION; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RASH; REVIEW; SEDATION; SOMNOLENCE; THROMBOCYTOPENIA; TREMOR; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ACUTE DISEASE; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BIPOLAR DISORDER; CLOZAPINE; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; HUMANS; LITHIUM; PIPERAZINES; PLACEBOS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; TREATMENT OUTCOME;

EID: 16244392390     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder [Revision]. Am J Psychiatry 2002;159 (suppl 4):1-50
2. Belmaker RH. Bipolar disorder. N Engl J Med 2004;351:476-486
3. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics for the treatment of bipolar disorder. J Clin Psychiatry 2005;66(suppl 3): 28-36
4. Ketter TA, Kalali AH, Weisler RH, for the SPD417 Study Group. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65:668-673
5. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl) 2000;150: 15-23
6. Weisler RH, Kalali AH, Ketter TA, and the SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65:478-484
7. McElroy SL, Keck PE Jr. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000;48:539-557
8. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998;155:12-21
9. Keck PE Jr, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry 2003;64:1426-1435
10. Tegretol [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002
11. Risperdal [package insert]. Titusville, NJ: Janssen Pharmaceutica Products, LP; 2003
12. Zyprexa [package insert]. Indianapolis, Ind: EH Lilly and Company; 2004
13. Seroquel [package insert]. Wilmington, Del: AstraZeneca Pharmaceuticals LP; 2004
14. Geodon [package insert]. New York, NY: Pfizer Inc; August 2004
15. Abilify [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2004
16. Hirschfeld RMA. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry 2003;64(suppl 8):15-21
17. Keck PE Jr, McElroy SL, Strakowski SM, et al. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000;61(suppl 4):33-38
18. Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057-1065
19. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-1017
20. AstraZeneca Pharmaceuticals. Available at: http://www.seroquel.com/ prof_asp/bipolar. Accessed September 13, 2004
21. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-748
22. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658
23. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-764
24. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000;61:638-642
25. Licht RW, Bysted M, Christensen H. Fixed-dosed risperidone in mania: an open experimental trial. Int Clin Psychopharmacol 2001;16:103-110
26. Tohen M, Zarate CA Jr, Centorrino F, et al. Risperidone in the treatment of mania. J Clin Psychiatry 1996;57:249-253
27. Vieta E, Herraiz M, Parramon G, et al. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J Affect Disord 2002;72:15-19
28. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002;3:1381-1391
29. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999;14:339-343
30. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-1226
31. Tohen M, Jacobs TG, Grundy SL, et al, for the Olanzapine HGGW Study Group. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000;57:841-849
32. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160:1263-1271
33. Tohen M, Sanger TM, McElroy SL, et al, for the Olanzapine HGEH Study Group. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-709
34. Tohen M, Chengappa KNR, Suppes T, et al. Relapse prevention in bipolar 1 disorder: 18-month comparison of olanzapine plus mood stabiliser v mood stabiliser alone. Br J Psychiatry 2004;184:337-345
35. McElroy SL, Frye M, Denicoff K, et al. Olanzapine in treatment-resistant bipolar disorder. J Affect Disord 1998;49:119-122
36. Zarate CA Jr, Narendran R, Tohen M, et al. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 1998;59:24-28
37. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex. sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63:1148-1155
38. Masand PS. Weight gain associated with psychotropic drugs. Expert Opin Pharmacother 2000;1:377-389
39. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66:51-57
40. McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J Clin Psychiatry 2002;63(suppl 3):15-20
41. Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999;60(suppl 21):16-19
42. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62(suppl 23):5-12
43. Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002;53:842-847
44. Adityanjee, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002;63(suppl 13):32-38
45. DelBello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41:1216-1223
46. Sachs G, Mullen JA, Devine NA. Quetiapine vs placebo as adjunct to mood stabilizer for the treatment of acute mania. Presented at the 3rd European Stanley Foundation Conference on Bipolar Disorder; Sept 12, 2002; Freiburg, Germany
47. Brecher M, Huizar K. Quetiapine vs placebo for acute mania associated with bipolar disorder (STAMP 1). Presented at the 5th International Conference on Bipolar Disorder; June 12-14, 2003; Pittsburgh, Pa
48. Jones M, Huizar K. Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1 and STAMP 2). Presented at the 5th International Conference on Bipolar Disorder; June 12-14, 2003; Pittsburgh, Pa
49. Mullen J, Devine J, Sweitzer D. Quetiapine adjunctive therapy for acute mania associated with bipolar disorder (SIAM). Presented at the 5th International Conference on Bipolar Disorder; June 12-14, 2003; Pittsburgh, Pa
50. Potkin SG, Keck P, Giller E, et al. Ziprasidone in bipolar mania: efficacy across patient subgroups. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
51. Keck PE, Potkin S, Warrington LE, et al. Efficacy and safety of ziprasidone in bipolar disorder, short- and long-term data. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
52. Segal S, Riesenberg RA, Ice K, et al. Ziprasidone in mania: double-blind, placebo-controlled trial. Presented at the American Psychiatric Association 55th Institute on Psychiatric Services; October 29-November 2, 2003; Boston, Mass
53. Keck PE Jr, Potkin SG, Dunn J, et al. Ziprasidone in bipolar mania: efficacy across patient subgroups. Presented at the 56th Institute on Psychiatric Services; October 6-10, 2004; Atlanta, Ga
54. Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 2003;64:532-539
55. Goodnick PJ. Ziprasidone: profile on safety. Expert Opin Pharmacother 2001;2:1655-1662
56. Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 2002;3:1773-1781
57. Weiden PJ, Loebel A, Yang R, et al. Course of weight & metabolic benefits 1 year after switching to Ziprasidone [poster]. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
58. Sanchez R, Bourin M, Auby P. Aripiprazole vs haloperidol for maintained treatment effect in acute mania. Presented at the 5th International Conference on Bipolar Disorder; June 12-14, 2003; Pittsburgh, Pa
59. McQuade R, Sanchez R, Carson W, et al. Efficacy of aripiprazole versus placebo in acute mania: pooled analysis. Presented at the 157th annual meeting of the American Psychiatric Association: May 1-6, 2004; New York, NY
60. Brambilla P, Barale F, Soares JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology (Berl) 2003;166: 315-332